Tag: multiple myeloma

1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events. 2. There was a 65% overall response rate seen in patients on the recommended dosage of teclistamab that persisted and increased overtime. Evidence Rating Level: 1 (Excellent) Study Rundown: Multiple myeloma is the second most common blood...
1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone. 2. Improved median progression-free survival and estimated survival rates two years after randomization in favor of the isatuximab group. Evidence Rating Level: 1 (Excellent) Study Rundown: Multiple myeloma (MM) remains an incurable hematologic malignancy, typically treated with immunomodulators...
1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone. 2. Improved median progression-free survival and estimated survival rates two years after randomization in favor of the isatuximab group. Evidence Rating Level: 1 (Excellent) Study Rundown: Multiple myeloma (MM) remains an incurable hematologic malignancy, typically...